NCT00741767

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (Advair and Quality of Sleep in COPD)

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Northwestern University · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if Advair Diskus improves sleep quality by reducing lung hyperinflation in COPD.

Detailed description

Chronic obstructive pulmonary disease (COPD) is a common and clinically important disease characterized by chronic, irreversible airflow obstruction. Poor sleep quality and insomnia are well described phenomena in patients with COPD. Several studies suggest sleep disturbance adversely affects quality of life and may worsen daytime pulmonary function in COPD patients. Improving sleep quality in patients with COPD, therefore, may not only improve health quality, but also attenuate the decline in daytime pulmonary function. Previous studies investigating the effects of inhaled bronchodilators on sleep quality in COPD have shown conflicting results. These conflicting data prompted us to perform a retrospective study on patients with COPD and co-existing sleep apnea (OSA) investigating the effects of mechanical lung function impairment and lung hyperinflation on sleep. Our study found a significant correlation between increased lung hyperinflation and reduced sleep efficiency (a measure of sleep quality), and this relationship was preserved in a multivariable regression model. We hypothesize that Advair Diskus improves sleep quality by reducing lung hyperinflation in COPD. To test this hypothesis, we propose a double-blinded, placebo controlled cross-over study of Advair Diskus in patients with COPD and lung hyperinflation. It was mutually decided by the sponsor and principal investigator to terminate the study early due to study subject enrollment difficulties.

Conditions

• Chronic Obstructive Pulmonary Disease
• Sleep Disorders

Interventions

Type	Name	Description
DRUG	salmeterol-fluticasone	250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily

Timeline

• Start date: 2008-08-01
• Primary completion: 2010-09-01
• Completion: 2012-02-01
• First posted: 2008-08-26
• Last updated: 2015-10-06

Locations

1 site across 1 country: United States